Cargando…
GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation
Anaplastic thyroid cancer (ATC) is a very rare, but extremely aggressive form of thyroid malignancy, responsible for the highest mortality rate registered for thyroid cancer. Treatment with taxanes (such as paclitaxel) is an important approach in counteracting ATC or slowing its progression in tumor...
Autores principales: | Molteni, Elisabetta, Baldan, Federica, Damante, Giuseppe, Allegri, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054879/ https://www.ncbi.nlm.nih.gov/pubmed/36983070 http://dx.doi.org/10.3390/ijms24065993 |
Ejemplares similares
-
Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells
por: Allegri, Lorenzo, et al.
Publicado: (2021) -
Role of m6A RNA Methylation in Thyroid Cancer Cell Lines
por: Allegri, Lorenzo, et al.
Publicado: (2022) -
Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line
por: Baldan, Federica, et al.
Publicado: (2015) -
The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells
por: Allegri, Lorenzo, et al.
Publicado: (2019) -
Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer
por: Yellapu, Nanda Kumar, et al.
Publicado: (2022)